Earnings and work loss from 5 years before to 5 years after bariatric surgery: A cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 09 03 2022
accepted: 21 04 2023
medline: 22 5 2023
pubmed: 18 5 2023
entrez: 18 5 2023
Statut: epublish

Résumé

The personal economic impact of bariatric surgery is not well-described. To examine earnings and work loss from 5 years before to 5 years after bariatric surgery compared with the general population. Nationwide matched cohort study in the Swedish health care system. Patients undergoing primary bariatric surgery (n = 15,828) and an equal number of comparators from the Swedish general population were identified and matched on age, sex, place of residence, and educational level. Annual taxable earnings (primary outcome) and annual work loss (secondary outcome combining months with sick leave and disability pension) were retrieved from Statistics Sweden. Participants were included in the analysis until the year of study end, emigration or death. From 5 years before to 5 years after bariatric surgery, earnings increased for patients overall and in subgroups defined by education level and sex, while work loss remained relatively constant. Bariatric patients and matched comparators from the general population increased their earnings in a near parallel fashion, from 5 years before (mean difference -$3,489 [95%CI -3,918 to -3,060]) to 5 years after surgery (-$4,164 [-4,709 to -3,619]). Work loss was relatively stable within both groups but with large absolute differences both at 5 years before (1.09 months, [95%CI 1.01 to 1.17]) and 5 years after surgery (1.25 months, [1.11 to 1.40]). Five years after treatment, bariatric surgery had not reduced the gap in earnings and work loss between surgery patients and matched comparators from the general population.

Sections du résumé

BACKGROUND
The personal economic impact of bariatric surgery is not well-described.
OBJECTIVES
To examine earnings and work loss from 5 years before to 5 years after bariatric surgery compared with the general population.
SETTING
Nationwide matched cohort study in the Swedish health care system.
METHODS
Patients undergoing primary bariatric surgery (n = 15,828) and an equal number of comparators from the Swedish general population were identified and matched on age, sex, place of residence, and educational level. Annual taxable earnings (primary outcome) and annual work loss (secondary outcome combining months with sick leave and disability pension) were retrieved from Statistics Sweden. Participants were included in the analysis until the year of study end, emigration or death.
RESULTS
From 5 years before to 5 years after bariatric surgery, earnings increased for patients overall and in subgroups defined by education level and sex, while work loss remained relatively constant. Bariatric patients and matched comparators from the general population increased their earnings in a near parallel fashion, from 5 years before (mean difference -$3,489 [95%CI -3,918 to -3,060]) to 5 years after surgery (-$4,164 [-4,709 to -3,619]). Work loss was relatively stable within both groups but with large absolute differences both at 5 years before (1.09 months, [95%CI 1.01 to 1.17]) and 5 years after surgery (1.25 months, [1.11 to 1.40]).
CONCLUSIONS
Five years after treatment, bariatric surgery had not reduced the gap in earnings and work loss between surgery patients and matched comparators from the general population.

Identifiants

pubmed: 37200271
doi: 10.1371/journal.pone.0285379
pii: PONE-D-22-07058
pmc: PMC10194874
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0285379

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK105948
Pays : United States

Informations de copyright

Copyright: © 2023 Norrbäck et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

Dr. Neovius reports receipt of advisory board fees from Itrim (a commercial vendor for lifestyle interventions) and Ethicon Johnson & Johnson. Dr. Näslund reports personal fees, outside the submitted work, from Baricol Bariatrics AB, Sweden, personal fees from Ethicon, Johnson & Johnson, and personal fees from AstraZenica A/S Denmark. Dr. Näslund is the previous director of the Scandinavian Obesity Surgery Registry. Dr. Ottosson reports personal fees as advisory board member for Ethicon Johnson & Johnson and for Vifor Pharma, and is the current director of the Scandinavian Obesity Surgery Registry. Dr. Norrbäck and Dr. Bruze declare that they have no conflict of interests.

Références

Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
JAMA. 2016 Oct 18;316(15):1595-1597
pubmed: 27755626
JAMA Surg. 2016 Mar;151(3):226-32
pubmed: 26444444
Lancet Diabetes Endocrinol. 2018 Mar;6(3):197-207
pubmed: 29329975
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Obesity (Silver Spring). 2013 Dec;21(12):2444-51
pubmed: 23520203
Obes Surg. 2012 Feb;22(2):259-65
pubmed: 20559894
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Int J Obes (Lond). 2021 Apr;45(4):766-775
pubmed: 33495524
JAMA. 2012 Jun 20;307(23):2516-25
pubmed: 22710289
Prev Med. 1997 Sep-Oct;26(5 Pt 1):734-44
pubmed: 9327484
Int J Obes Relat Metab Disord. 1999 Jun;23(6):619-24
pubmed: 10411235
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31917447
Obes Surg. 1991 Jun;1(2):137-140
pubmed: 10775905
JAMA. 2014 Jun 11;311(22):2297-304
pubmed: 24915261
Surg Obes Relat Dis. 2010 Jan-Feb;6(1):8-15
pubmed: 19782647
Obes Surg. 2007 Apr;17(4):434-7
pubmed: 17608252
Obes Surg. 2010 Mar;20(3):340-5
pubmed: 19352783
Ann Rheum Dis. 2014 May;73(5):845-53
pubmed: 23520035
PeerJ. 2015 Sep 29;3:e1285
pubmed: 26468438
Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):160-169
pubmed: 27899816
Ann Rheum Dis. 2013 May;72(5):672-7
pubmed: 22679306
Surg Obes Relat Dis. 2005 Jul-Aug;1(4):413-6; discussion 417
pubmed: 16925260
J Health Econ. 2015 Sep;43:244-68
pubmed: 26279519
Scand J Work Environ Health. 1998 Feb;24(1):54-61
pubmed: 9562401
Obesity (Silver Spring). 2009 May;17(5):941-64
pubmed: 19165161
Lancet. 2017 Mar 25;389(10075):1229-1237
pubmed: 28159391
J Intern Med. 2013 Mar;273(3):219-34
pubmed: 23163728
Surg Obes Relat Dis. 2021 Mar;17(3):606-614
pubmed: 33243667
Obes Rev. 2009 Jan;10(1):17-27
pubmed: 18778315
Obes Surg. 2015 Oct;25(10):1893-900
pubmed: 25703826
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Obes Surg. 2017 Sep;27(9):2246-2252
pubmed: 28293901
Clin Obes. 2019 Feb;9(1):e12290
pubmed: 30458582
Int J Obes (Lond). 2012 Mar;36(3):356-62
pubmed: 21364529

Auteurs

Mattias Norrbäck (M)

Department of Medicine, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden.

Martin Neovius (M)

Department of Medicine, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden.

Johan Ottosson (J)

Faculty of Medicine and Health, Department of Surgery, Örebro University, Örebro, Sweden.

Ingmar Näslund (I)

Faculty of Medicine and Health, Department of Surgery, Örebro University, Örebro, Sweden.

Gustaf Bruze (G)

Department of Medicine, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH